Horizon Discovery Sign License Agreement with Ortho Biotech Oncology Research & Development
News Aug 04, 2009
Horizon Discovery (Horizon) has announced it has signed a commercial agreement with Janssen Pharmaceutica NV, relating to its X-MAN technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalized’ medicine.
The agreement covers the licensing of certain X-MAN cell lines including major cancer causing genes and their matched normal genetic backgrounds. The approach should enable J&J to gather information relating to the selectivity and mode-of-action of their compounds using model in-vitro systems.
“Dr Darrin M Disley, Chairman of Horizon says “it has always been our aim to work with leading players in the Rx and Dx space and we hope to build a long and productive relationship moving forward”
Janssen Pharmaceutica NV will pay Horizon undisclosed up-front and renewal fees during the term of the agreement. Work between the parties will begin in August 2009.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
The Ancient Behaviour of Sleep, Conserved Throughout EvolutionNews
The finding that jellyfish sleep implies that sleep is an ancient behavior, largely untouched by millennia of evolution.READ MORE
Gene Immunotherapy Approach Prevents and Reverses Symptoms of Multiple SclerosisNews
Researchers used a viral vector to deliver a gene encoding a myelin sheath protein to the liver, thereby inducing robust and durable immune tolerance in mice by preventing T cells from attacking the myelin sheath.READ MORE